PALI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.023

-96.62%

-0.040

-91.49%

-0.070

-87.93%

Estimates Revision

The market is revising No Change the revenue expectations for Palisade Bio, Inc. (PALI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 209.12%.

EPS Estimates for FY2025

Revise Downward

-65.11%

In Past 3 Month

Stock Price

Go Up

+209.12%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast PALI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PALI is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.830

Low

8.00

Averages

8.00

High

8.00

Current: 1.830

Low

8.00

Averages

8.00

High

8.00

Maxim

Buy

maintain

$2 -> $8

2025-11-11

Reason

Maxim

Price Target

$2 -> $8

2025-11-11

maintain

Buy

Reason

Maxim raised the firm's price target on Palisade Bio to $8 from $2 and keeps a Buy rating on the shares, citing lower risk as the firm contends that the company's recent financing supports trials for '2108 and potential approval.

Valuation Metrics

The current forward P/E ratio for Palisade Bio Inc (PALI.O) is -8.29, compared to its 5-year average forward P/E of -1.28. For a more detailed relative valuation and DCF analysis to assess Palisade Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.28

Current PE

-8.29

Overvalued PE

0.38

Undervalued PE

-2.94

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

8.57

Current PS

0.00

Overvalued PS

30.51

Undervalued PS

-13.38

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PALI News & Events

Events Timeline

No data

News

2.0

11-28Benzinga

Tilray Brands, SuperX AI Technology, and Other Major Stocks Decline in Friday's Pre-Market Trading

5.0

11-20CNBC

Hyundai unveils new rugged concept SUV to highlight off-road aspirations

5.0

10-28Newsfilter

Palisade Bio Names Sharon Skare as Vice President and Global Head of Clinical Operations

People Also Watch

Frequently Asked Questions

What is Palisade Bio Inc (PALI) stock price today?

The current price of PALI is 1.83 USD — it has decreased -5.67 % in the last trading day.

What is Palisade Bio Inc (PALI)'s business?

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

What is the price predicton of PALI Stock?

What is Palisade Bio Inc (PALI)'s revenue for the last quarter?

Palisade Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Palisade Bio Inc (PALI)'s earnings per share (EPS) for the last quarter?

Palisade Bio Inc. EPS for the last quarter amounts to -0.38 USD, decreased -83.62 % YoY.

What changes have occurred in the market's expectations for Palisade Bio Inc (PALI)'s fundamentals?

How many employees does Palisade Bio Inc (PALI). have?

Palisade Bio Inc (PALI) has 8 emplpoyees as of December 15 2025.

What is Palisade Bio Inc (PALI) market cap?

Today PALI has the market capitalization of 289.07M USD.